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Abstract
The urate transporter, GLUT9, is responsible for the basolateral transport of urate in the proximal tubule of human kidneys
and in the placenta, playing a central role in uric acid homeostasis. GLUT9 shares the least homology with other members of
the glucose transporter family, especially with the glucose transporting members GLUT1-4 and is the only member of the
GLUT family to transport urate. The recently published high-resolution structure of XylE, a bacterial D-xylose transporting
homologue, yields new insights into the structural foundation of this GLUT family of proteins. While this represents a huge
milestone, it is unclear if human GLUT9 can benefit from this advancement through subsequent structural based targeting
and mutagenesis. Little progress has been made toward understanding the mechanism of GLUT9 since its discovery in 2000.
Before work can begin on resolving the mechanisms of urate transport we must determine methods to express, purify and
analyze hGLUT9 using a model system adept in expressing human membrane proteins. Here, we describe the surface
expression, purification and isolation of monomeric protein, and functional analysis of recombinant hGLUT9 using the
Xenopus laevis oocyte system. In addition, we generated a new homology-based high-resolution model of hGLUT9 from the
XylE crystal structure and utilized our purified protein to generate a low-resolution single particle reconstruction.
Interestingly, we demonstrate that the functional protein extracted from the Xenopus system fits well with the homology-
based model allowing us to generate the predicted urate-binding pocket and pave a path for subsequent mutagenesis and
structure-function studies.
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Introduction
GLUT9 (SLC2A9) membrane transporter is distinct among
other members of the glucose transporters (GLUT or SLC2)
family due to its substrate specificity and sequence identity. While
the majority of 14 members of the GLUT superfamily transports
glucose or other monosaccharides [1], GLUT9 was shown to
transport essentially urate [2,3]. Transepithelial urate transport is
of critical importance to urate homeostasis in humans, as the lack
of the urate catabolizing enzyme uricase elevates the serum uric
acid (SUA) levels six to ten times compared to other mammals
with functional uricase. High SUA levels increase the risk for uric
acid precipitation illustrated by gout flairs, tophi and kidney stone
formation, but hyperuricemia, independent of crystal formation,
has also been linked with hypertension, atherosclerosis, insulin
resistance, and diabetes [4]. Uric acid excretion depends for about
one third on intestinal secretion and for about two-thirds on the
complex transport (reabsorption and secretion) in the proximal
tubule of the kidney. Reabsorption depends mainly on the
transport activity of the apical SLC22A11 (URAT1) and the
basolateral SLC2A9 (GLUT9), while secretion is driven by the
ATP-dependent ABCG2. Loss of function mutations in both
SLC22A11 and SLC2A9 conduct to familial hypouricemia, an
autosomal recessive trait characterized by hypouricemia, increased
fractional excretion of uric acid and increased risk of exercise-
induced acute renal failure. Single nucleotide polymorphisms in
the SLC2A9 genes have also been associated with gout, coronary
artery disease, and myocardial infarction [5].
All 14 GLUT members share common structural features such
as 12 transmembrane helices, cytoplasmic amino and carboxy
termini, and an N-linked glycosylation site, although the
glycosylation site varies across the family. Regarding GLUT9,
two isoforms, SLC2A9a and SLC2A9b, have been described
encoding the two proteins hGLUT9a and b that differ only by the
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first 29 residues of the N-terminal domains [6]. GLUT9a is
expressed ubiquitously, while GLUT9b is restricted to the main
organs involved in urate transport, such as liver and kidney [7].
GLUT9-mediated urate transport has been characterized. It is
independent of sodium, chloride and anions, but is voltage-
dependent and currents have been recorded at physiological pH.
Altogether, the data provided so far are compatible with a
transport model in which GLUT9 is a uniport, without having
formally excluded all other possibilities.
The question remains how similar GLUT9 is to other members
of the GLUT family. Like GLUT1-4, it was demonstrated that
GLUT9 is capable of transporting monosaccharides when
heterologously expressed in X. laevis oocytes. However, this
finding is controversial as the rate reported is very low and in-vivo
transport is unlikely [8]. Pharmacologically, GLUT9 is not
inhibited by cytochalasin B, a powerful non-competitive inhibitor
of glucose transport across the GLUT family. Furthermore, the
group of Thorens reported that deletion of Glut2 in the liver
blocked glucose uptake in murine hepatocytes even with high
expression levels of Glut9 present, indicating Glut9 is not
responsible for physiological uptake of glucose [9]. It is apparent
that the relationship between GLUT9 and other members of the
glucose transporting family is quite complex and further work
must be done to advance our understanding of this atypical
transporter.
Human membrane proteins are difficult to express for
subsequent purification and structural analysis. However, the
knowledge of a structure yields significant advancements toward
an understanding of detailed mechanism of substrate binding and
transport. Modeling could reveal distinct pockets required to
facilitate substrate movement as well as potential binding sites for
modulators leading to pharmacological advancement and clinical
development. Little was known about the detailed structure of
GLUTs, in particular hGLUT9. Some biochemical approaches,
such as cysteine scanning, did reveal a basic topological model of
GLUT transporters [10]. Additionally, a homology model was
generating based on the glycerol-3-Phosphate antiporter (PDB ID:
1PW4) [11]. Unfortunately, the template structure shares little
relevance to hGLUT9 as the sequence alignment coverage
represents only short regions with a total of 31% of the protein.
Of the 31% aligned, the homology had only 36% identity with
hGLUT9 indicating the need for further information before
structure-function studies could be initiated. The 2012 publication
of a high-resolution crystal structure of the bacterial homologue,
XylE was an informative breakthrough allowing structural insights
into the glucose transport. XylE transports the monosaccharide D-
xylose and in the original work, Sun et. al established models for
the glucose transporting members of the SLC2 family, hGLUT1-
4. However, even with publication of the XylE structure, it is
unclear if other members of the hGLUT family, and in particular
hGLUT9, could be modeled in the same fashion as GLUT1-4.
Based on homology, and substrate specificity, GLUT9 diverges
from the rest of the group. In this work, we establish a new
homology-based model for hGLUT9, based on the crystal
structure of XylE. We further detail the functional expression
and purification of hGLUT9 in X. laevis oocytes. Finally, we
utilized our purified protein to generate a single particle
reconstruction of isolated monomeric human GLUT9. As
expected, the low-resolution reconstruction merges well with the
homology-based model, providing initial support for the use of our
predictive model as a tool for subsequent structure-function
studies. We conclude by demonstrating the potential of the
homology-based model to uncover the binding pocket for
hGLUT9’s unique substrate urate.
Materials and Methods
Ethics Statement
All animal experiments were in accordance with the Swiss
animal welfare law and were approved by the local Veterinary
Authority Bern (Veterina¨ramt Bern; Permit Number: BE26/12).
Materials
We purchased Superose 6 10/300 GL from Amersham
Biosciences (#17-5172-01, GE Healthcare Europe, Glattbrugg,
Switzerland); sodium dodecyl sulphate (SDS) from Sigma-Aldrich
(#L6026, St. Louis, MO, USA); n-Dodecyl-ß-D-Maltopyranoside
(DDM) from Affymetrix (#D310, St. Clara, CA, USA). Human
Rhinovirus (HRV) 3C protease was purchased from AG Scientific
(#H-1192, San Diego, CA, USA).
Computational Analysis
Amino acid identity and relationships between bacterial and
human SLC2 homologue were performed using the ClustalW2.1
program [12] with the BLOSUM matrix. The NCBI reference
sequence numbers used was NP_418455.1 (XylE), NP_006507.2
(SLC2A1), NP_000331.1 (SLC2A2), NP_008862.1 (SLC2A3),
NP_001033.1 (SLC2A4), NP_064425.2 (SLC2A9a) and
NP_00100190.1 (SLC2A9b). Phylogenetic tree generation of
SLC2 family members was based on the results from the
BLOSUM matrix within SeaView 4 software (distance measure-
ment method using BioNJ algorithm with Poisson parameter) [13].
EasyModeller 2.1 [14] was used to build the predicted structure of
hGLUT9 from its FASTA sequence NP_064425.2 using the
crystal structure of the bacterial homologue XylE (PDB ID:
4GBY) as a template. The Orientation of Proteins in Membrane
Database (PPM Server) calculates rotational and translational
positions of hGLUT9 protein within membrane bilayer using their
predictive 3D-structure (PDB coordinate file) as an input [15].
Human GLUT9b (SLC2A9) Sub-Cloning
cDNA from hGLUT9b (Gene ID: 56606) was purchased from
Origene and sub-cloned by PCR into the pMJB08 expression vector
using forward primers 59 CAT TTC TCG AGA TGA AGC TCA
GTA AAA AGG ACC GAG G9 and reverse primers 59 TTA ATT
CTA GAT TAA GGC CTT CCA TTT ATC TTA CCA TC 39.
PCR products were digested with the restriction enzymes XhoI and
XbaI, and ligated into the vector. The recombinant protein was
tagged with an N-terminal, 10xHis, FLAG tag, and human
rhinovirus 3C protease (HRV 3C) cleavage site known as
PreScission followed by a hemaglutinin (HA) tag [16].
Oocytes were prepared and injected at stage V-VI with 20 ng of
cRNA encoding SLC2A9b. In brief, animals were anesthetized by
cooling at 4uC with tricaine mesylate (3-aminobenzoic acid ethyl
ester, methane sulfonate salt, 150 mg/l). Small pieces of ovary
were isolated in sterile Barth solution (10 mM HEPES pH 7.4,
88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.82 mM MgSO4,
0.33 mM Ca(NO3)2, and 0.41 mM CaCl2, supplemented with
50 mg/ml gentamycin). Oocyte defolliculation occurred in calci-
um-free modified Barth’s solution with 3 mg/ml collagenase NB4
(SERVA Electrophoresis, Heidelberg, Germany). Isolated oocytes
were then incubated overnight in standard Barth’s solution. After
24 hours, injection of cRNA was performed in at least 1,500
oocytes using an automated injection device (Roboinject, Multi
Channel Systems, Reutlingen, Germany). Oocytes were main-
tained in Barth’s Solution for 3 days at 18uC to maximize
expression for functional and biochemical studies.
Structural Insights for the hGLUT9
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Xenopus laevis Expression
Oocytes were solubilized and crudely homogenized using a
100 ml pipette tip with ice-cold RIPA lysis buffer as described
previously [17]. After 45 min on ice, samples were centrifuged at
15,000 g (15 min at 4uC). Only the supernatant below the yolk
was taken for SDS-PAGE and Western blot analysis.
Protein Deglycosylation
For deglycosylation experiments, oocytes were solubilized as
described above with modified SDS-free RIPA buffer (20 mM
Tris?Cl pH 7.4, 150 mM NaCl, 0.5% DDM, 1% NP-40, 0.5%
DOC) supplemented with 1 mM PMSF and EDTA-free protease-
inhibitor cocktail. Following solubilisation, the manufacturer’s
protocol was followed for enzymatic deglycosylation (The Protein
Deglycolsylation Mix, NEB, #P6039, Ipswich, MA, USA). In
brief, 40 mg of total protein were incubated in glycoprotein
denaturing buffer for 30 min at 37uC. Solution was diluted in G7
reaction buffer with NP-40 and PNGase was added for 1 hr at
37uC. Samples were analyzed by SDS-PAGE and Western blot.
Plasma-Membrane Biotinylation
A minimum of 20 hGLUT9-injected oocytes and 20 water-
injected oocytes were washed twice in phosphate buffered saline
(PBS). Oocytes were subsequently incubated in PBS supplemented
with 1.5 mg/ml LC-Sulfo-NHS Biotin (Molecular BioScience,
#00598, Boulder, CO, USA) for 60 min at 4uC under gentle
agitation. Oocytes were washed by 3 successive baths of PBS
containing 100 mM glycine to stop the reaction, followed by a
final rinse in PBS to remove excess glycine. Oocytes were
transferred to pre-cooled Eppendorf tubes with ice-cold RIPA
lysis buffer added to a final volume of 1 ml. Cells were crudely
homogenized and incubated for 120 min at 4uC under rotation. In
parallel, a final volume of 37 ml of streptavidin beads (Thermo
Scientific, #20349, MA, USA) were prepared washed and
equilibrated into 1 ml of RIPA lysis buffer for each sample to be
tested. Beads were centrifuged at 9,000 g and the RIPA
supernatant was removed. After the 120 min sample incubation,
lysates were centrifuged at 15,000 g for 15 min at 4uC. Equal
amounts of supernatant (approximately 500 ml) were transferred to
the previously prepared streptavidin beads. Samples were incu-
bated O/N at 4uC under rotation. Samples were then centrifuged
at 9,000 g for 1 minute at 4uC. After incubation, 50 ml of the
supernatant was retained corresponding to the cytoplasmic
fraction. Beads were subsequently washed 3 x times in 1 ml of
RIPA buffer. Beads were spun down and excess supernatant was
removed. Protein was eluted from the beads by addition of 100 ml
of 2X SDS-loading buffer containing DTT and membrane
fraction was heated for 15 min at 95uC. Centrifuge beads for
1 min at 4uC at 9,000 g and load 25 ml of supernatant for SDS
PAGE and Western blot analysis.
SDS-PAGE and Western Blotting
Protein concentrations were determined using a BCA protein
assay kit (Thermo Scientific, MA, USA). For SDS-PAGE, samples
were prepared on 8% polyacrylamide gels and transferred to
PVDF membranes (Amersham). Monoclonal HA-epitope anti-
bodies (a-HA) were purchased from Sigma-Aldrich (#H3663, St.
Louis, MO, USA) and used at a final dilution of 1:1000.
Immunodetection was performed using goat anti-mouse IgG
(1:3000) (H+L) horseradish peroxidase (Bio-Rad, #172-1011,
Hercules, CA, USA) with an enhanced chemiluminescence
detection system (Amersham Biosciences, GE Healthcare Europe,
ECL+ #RPN2106, Glattbrugg, Switzerland).
Electrophysiology
Oocytes were impaled with two electrodes filled with 3 M KCl,
and their membrane potentials were maintained at 260 mV
throughout the experiment. All recordings were performed at
18uC and superfused with OR2 medium (5 mM HEPES pH 7.4,
82.5 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl2 and 1 mM
MgCl2,). Currents were recorded using an automated process
equipped with standard two-electrode voltage clamp (TEV)
configuration (Multi Channel Systems, Reutlingen, Germany).
Data was analysed using Excel (Microsoft, Redmond, WA)
software. Uric acid was prepared directly before usage in the
recording medium to obtain the desired test concentrations. All
experiments were carried out using three or more X. laevis
oocytes.
Total Membrane Preparation
Oocytes were homogenized with a Teflon-glass homogenizer in
lysis buffer containing 50 mM Tris?Cl pH 8.0 supplemented with
protease inhibitor cocktail (Sigma-Aldrich, #S8830, St. Louis,
MO, USA) and 1 mM PMSF and fixed on rotator at 400 rpm
(Homogenisator Potter S, B. Braun, Melsungen, Germany).
Homogenates were centrifuged at 1,500 g for 15 min at 4uC to
discard nuclear and cellular debris. Supernatant was centrifuged at
150,000 g for 1 hr at 4uC to pellet down total membranes.
Membranes pellets were resuspended in lysis buffer with 1 M
NaCl to solubilize contaminant membrane associated proteins
(e.g. vitellogenins) and further centrifuged at 150,000 g for 1 hr at
4uC [16]. The final membrane pellet was resuspended in 20 mM
Tris?Cl pH 8.0, 300 mM NaCl and 10% (v/v) glycerol at about
20 mg/ml and stored at 280uC.
Ion Metal Affinity Chromatography (IMAC) Purification of
hGLUT9b and Size Exclusion Chromatography (SEC)
Membranes suspensions were diluted to 2.5 mg/ml final
concentration in 50 mM Tris?Cl pH 8.0, 1 M NaCl supplemented
with protease inhibitor cocktail and PMSF. DDM (D/P ratio = 15)
was used to solubilized membranes at 4uC for 2.5 hrs under gentle
rotation. The lysates were centrifuged at 5,000 g for 5 min at 4uC
and supernatant was loaded on a cobalt column and incubated
overnight (14 mg total protein/ml settled gel, equilibrated with
20 mM Tris?Cl pH 8.0, 300 mM NaCl, 0.1% DDM with 5 mM
Imidazole). The resin was washed 2 times with equilibration buffer
containing 40 mM imidazole (10 resin volumes). SLC2A9b was
eluted by incubation with Human Rhinovirus (HRV) 3C protease at
70 mg/ml for 2 hrs at 4uC under constant agitation. After elution,
the protein was concentrated to final volume of 70 ml using an
Amicon 50 kDa cut-off centrifugal filter (Millipore, #051382, MA,
USA). A Superose 6 10/300 GL gel filtration column was
connected to A¨KTAprime workstation (GE Healthcare) and
equilibrated with 20 mM Tris?Cl pH 8.0, 150 mM NaCl, 0.1%
DDM. The solution was filtered at 0.22 mm and sonicated in a
water bath for 5 min to minimize bubble formation. Sample was
eluted with equilibrium buffer at a flow rate of 0.3 ml/min.
Absorbance at 280 nm was monitored with in-line UV-detector and
all fractions of 500 ml were collected and analysed.
Negative-Stain TEM and Single Particle Reconstruction
(SPR)
Negative-stain TEM and grid preparation was performed as
described [17]. In brief, solubilized hGLUT9b (15 mg/ml) was
adsorbed for 10 seconds to parlodion carbon-coated hydrophobic
copper grids. Grids were washed in ddH20 and negatively stained
with 0.75% (w/v) uranyl acetate. Electron micrographs were
Structural Insights for the hGLUT9
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recorded at a magnification of 110,0006 on a Morada CCD
camera from OLYMPUS where pixel size was 3.092 A˚. The
Philips CM-12 electron microscope operated at 80-kV accelera-
tion voltage.
Single Particle Reconstruction (SPR) was performed using
EMAN2 (Electron Micrograph ANalysis) open-source suite
programs [18]. Digital TIFF images (297062100) were recorded
in 16-bit using the software iTEM (OLYMPUS) under constant
focus and astigmatism corrections. Standard EM parameters were
used to capture micrographs. The images were obtained free of
drift, vibration and astigmatism, with slight under-focus controlled
by the iTEM software during live acquisition. A detailed process of
the subsequent SPR is described below.
i. Particle selection (e2boxer.py)
Contrast level were adjusted by Photoshop CS suite for each
micrographs and saved in 8-bit. Electron micrographs were import
in EMAN2 suite. In EMAN2, all program are executed using the
built-in workflow GUI (e2workflow.py). We apply a number of
common filters to the data before importing such as Edge nom
thought e2workflow.py program. All micrographs are saved as
‘‘MRC’’ (Medical Research Council) files. Particles were selected
with box dimension 84684 pixels as 7056-dimensional vector
using semi-automatic picking function by Swarm mode (algorithm
uses a trainable heuristic based approach) in e2boxer.py program.
The results were manually verified, and false positives were
eliminated, at this step of the process image quality weight can be
addressed 0 to 4. When all particles are selected output can be
written with box coordinates. Images were normalized by the
normalize.edegemean option. Output images were saved in
default format ‘‘BDB’’files used for processing in the workflow
interface.
ii. CTF and phase flipping corrections (e2ctf.py)
The aim of SPR is to generate the ‘‘true’’ 3D structure of a
macromolecule based on its 2D projections. Inherent of contrast
transfer function (CTF) and the envelope function of the electron
microscope, the projections observed are not reflective of the real
projections of the electron density of the specimen. CTF is a
mathematical representation of the imaging process in the TEM,
examined in reciprocal space. Begin with selecting the particles
intended to generate the CTF parameters using the following
steps: i/Autofit, ii/manually fine-tune parameters for a few sets at
different defocuses iii/generate a structure factor using these sets
iv/re-run autofit v/manually check the fitting results. In practice,
2D power spectra and 1D averaged power spectrum of the boxed
out particles from each single image is used to characterize the
CTF with three parameters: defocus, B-factor and %AC
(Amplitude Contrast). The particle set is built from phase-flipped
output. The Phase-flipping corrections simply consist of multiply-
ing the Fourier transform of each particle image by -1 over the
appropriate frequency ranges.
iii. Reference-free class averages (e2refine2d.py)
In this step, the strategy is to sort raw particles presenting the
same orientations into different groups based solely on their 2D
projection characteristics. A set of representative class-averages is
generated and only used to assess the structural variability of the
specimen and to create an initial 3D-model. The result is a
reduction of the noise level to give a shape more detailed from
specific or ‘‘class’’ angles of the specimen corresponding to the
different views.
iv. Initial model building (e2initialmodel.py)
This program called e2initialmodel uses class-averages pro-
duced to create few initial models classified by quality for use in
further refinement. Based on the crystal structure of XylE,
hGLUT9 was assumed to be asymmetrical. Therefore, we utilized
the Asymmetrical C1 parameter within the program to generate
the initial model. The 3D-model generated from the class averages
was used to accommodate the predicted homology-based model of
hGLUT9 and for further refinement within SPR.
v. Refinement and Resolution (e2refine.py, e2eotest.py, e2re-
solution.py)
Based on the initial model, back projections in all obtained
orientations are generated and computationally compared to the
original 2D-projections to identify similarities among the individ-
ual classes. Sets of more similar projections are iteratively aligned
and averaged. Class-averages, for which the orientation in known,
as defined by the initial model, are used to build a new, more
refined, 3D-model. Three iterations and the generated Fourier
Shell Correlation curve at 0.5 were used to define the resolution of
the reconstruction at 23 A˚.
Results
Predicted Structure of Human SLC2A9 (hGLUT9)
Recently, JIANG et al. published the high-resolution structure
of the bacterial SLC2 homologue XylE co-crystallized with its
substrate D-xylose. From these results, (JIANG) reconstructed the
human SLC2A1 (GLUT1) protein structure from sequence
homology validated by further mutagenesis experiments [19].
Due to the diversity present within the SLC2 family of human
proteins, it was not known whether additional members could be
reconstructed in the same manner. To determine the relationship
and sequence homology between different SLC2 members and
their bacterial homologue XylE, a ‘‘heat map’’ matrix and
associated phylogenic tree was generated (Figure 1A) based on
the NCBI BLAST alignment shown in Figure S1. SLC2A(1–4)
have high sequence identity and similarity averaging 58 and 74%,
respectively. With respect to XylE, SLC2A(1–4) share 29%
identity and 49% sequence similarity. However, SLC2A9 isoforms
share a more distant relationship to both SLC2A(1–4) and XylE
with average sequence identities and similarities at 36/56% and
24/45%, respectively. The relative distances between homologues
is better represented by the phylogenic tree analysis (Figure 1B)
showing clear separation of SLC2A9 from other human GLUT
proteins.
In order to determine if it was possible to derive an accurate
structure of hGLUT9, a predictive homology-based model
structure was designed enabling subsequent validation using low-
resolution structural, biochemical, and functional analysis. The
program EasyModeller 2.1 was used to construct the predicted
structure of hGLUT9 from its FASTA sequence NP_064425.2
using the crystal structure of a bacterial homologue named XylE
(PDB ID: 4GBY). The structure obtained is similar to the bacterial
homologue composed of 12 transmembrane segments (TMs) and
of one intracellular domain (Figure 2A). The human protein
contains an additional unfolded long C-terminal domain (C-ter)
not present in the bacterial homologue. From the generated
hGLUT9 structure, a schematic topology representation depicting
Structural Insights for the hGLUT9
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transmembrane helices was realized using OPM Database
(Figure 2B, insert). Depth/hydrophobic thickness is 26.86
2.2 A˚ with DGtransfer =255.5 kCal/mol and tilt angle = 661u.
The TexTopo program was used to represent topology of the
protein showing only transmembrane helix part: TM1 (G13-E35),
TM2 (A64-Y89), TM3 (T105-G124), TM4 (L167-M187), TM5
(S200-T215), TM6 (F235-F251), TM7 (V318-T339), TM8 (T357-
V374), TM9 (L383-T403), TM10 (I416-T438), TM11 (F451-I472)
and TM12 (Y478-L495) in Figure 2B.
Expression Analysis of GLUT9 in Xenopus laevis Oocyte
System
The X. laevis oocytes expression system was chosen to express
hGLUT9 due to the unique capabilities that allow for high protein
expression and moderate-throughput functional characterization
within the same expression vector. The goal was to begin
validation by functional expression, purification and reconstruc-
tion of hGLUT9 and comparison to the homology-based model
predicted from XylE.
We sub-cloned the cDNA of SLC2A9b into a vector containing
an N-terminal purification tag. cDNA was in vitro-transcribed into
cRNA and injected into Xenopus laevis oocytes. Western blot
analysis of membrane preparations correlating to the amount of
protein isolated from individual or fractional oocytes demonstrated
that GLUT9 is highly expressed in oocytes with protein levels
detected in as low as J of an oocyte (Figure 3A).
To validate the surface expression of GLUT9 two independent
protocols were performed: surface biotinylation to label and pull
down only protein expressed on the plasma membrane and
protein deglycosylation analysis, to determine if there is a Western
blot shift due to enzymatic removal of extracellular glycans.
Figure 3B demonstrates a 10 kDa shift for hGLUT9 treated with
the non-specific deglycosylating enzyme PNGase indicating proper
protein folding within the ER and subsequent surface expression.
This observation was confirmed through membrane biotinylation
pull-down in Figure 3C. Water-injected and hGLUT9-injected
oocytes were surface-labelled with biotin. Cells were lysed and
total protein was incubated on streptavidin beads. Protein isolated
from the beads contains only the surface membrane fraction and
expression is clearly enriched in hGLUT9-injected oocytes,
whereas the cytosolic supernatant fraction shows clear actin
binding but little to no hGLUT9, indicative of high-levels of
surface protein expression.
Functional Analysis of hGLUT9 in Xenopus laevis Oocyte
System
Functional surface expression was determined using an auto-
mated two electrodes voltage clamp system (HiClamp). Oocytes
were exposed to 500 mM uric acid for 20 sec, water injected
oocyte as negative control, was measured (n = 5). The water
injected oocyte showed no effect to uric acid, whereas the cRNA
injected oocytes showed an outward current of 8068 nA while the
oocyte was clamped at 260 mV (Figure 4A). The current
behaviour was also measured for untagged protein indicating that
the N-terminal modification had no impaired on the expression
level or on functional level (data no shown). We also observed
inhibition of SLC2A9 activity through application of 25 mM
phloretin, a non-specific GLUT9 inhibitor (Figure 4B). GLUT9
Figure 1. Phylogenetic tree and sequence relationships of the SLC2 family members. (A) Bacterial XylE sequence identity and similarity
heat map comparing various members of the human GLUT transporter family. SLC2A9a and b share the least sequence similarities and identities
when compared to SLC2A1–4 and are further separated from the bacterial homologue XylE. (B) Phylogenic tree representation of the relationship
between GLUT family members.
doi:10.1371/journal.pone.0108852.g001
Structural Insights for the hGLUT9
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e108852
was activated with 500 mM uric acid followed directly by
application of phloretin in the presence of uric acid. This resulted
in a reduction of 45%65% of transporter activity (n = 8)
corresponding nicely to previously described radioactive uptake
studies [3]. Water-injected oocytes displayed no alterations of
current activity in the presence of phloretin (Data not shown).
Purification of GLUT9 by IMAC and SEC
After demonstrating that hGLUT9 is functionally active at the
surface membrane of oocytes, work was performed to optimizing
the purification methods required for further structural studies
with a focus on maintaining physiological conformation. The
correct choice of detergent is crucial to maintain a functional
representative and stable form of solubilized membrane proteins.
DDM, a mild non-ionic detergent, commonly used for the
solubilisation of GPCRs [20] was shown to completely extract
and solubilize GLUT9 from membrane preparations in silver
staining (Figure 5A). P5000 represents the insoluble membrane
fraction remaining after detergent extraction. This indicates that
the detergent efficiently solubilized membrane proteins as the
majority of the signal remains in the soluble Input fraction. The
Input lane corresponds to the total soluble membrane lysate. The
Unbound is the membrane lysate remaining after incubation with
cobalt resin and represents total membrane lysate minus protein
bound. The final Wash columns reveal the removal of non-specific
low-affinity resin binding proteins and the Elution column
Figure 2. Homology-based modeling of hGLUT9 structure. The 3D-structural model of hGLUT9 is generated from sequence alignment with
the bacterial homologue XylE. (A) Merge of hGLUT9 (green) and XylE (blue) 3-D structures: visualized with PyMOL v0.99 software. Even with the
decreased homology of hGLUT9 versus GLUT1–4, the putative topological model corresponds to the one of XylE. (B) Putative 3D-structure generated
by EasyModeller 2.1 embedded within a simulated bilayer as calculated from hydrophobicity charge analysis. Representation of the putative model is
translated into a 2-D topological map. Note that only trans-membrane helices are represented, with exclusion of the large cytoplasmic helices
between transmembrane VI and VII.
doi:10.1371/journal.pone.0108852.g002
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represents the purification and extraction of hGLUT9 using the
sequence specific HRV-3C protease from the cobalt resin. The use
of the oocyte system for the purification of membrane proteins
produces significant purified protein however the amount is
typically much lower than canonical purification methods making
the final elution on silver stain difficult to ascertain. Additional
immune-specific techniques such as Western blotting must be used
in parallel to determine the quality of the final purified protein
[16,17]. Using the same gel, Western blotting demonstrates strong
signal in the elution indicating significant enrichment (Fig-
ure 5B). GLUT9 was isolated using IMAC (Immobilized Metal
Affinity Chromatography) as a monomer (,60 kDa), oligomer
(,120 kDa) and aggregate (.150 kDa) from membrane prepara-
tions of 1500 oocytes.
Size exclusion chromatography (SEC) was performed using the
eluted fractions after IMAC. The aim was to create a homogenic
purified protein extract by separating the aggregated and
oligomeric forms from the monomeric state (Figure 6A). Fraction
35 was determined to proportionally yield the most monomeric
protein with minimal overlap from oligomeric states (Figure
S2A). Figure 6B demonstrates the isolated 60 kDa monomer as
represented on silver stain and indicates isolation and purification
of the monomeric form of hGLUT9. While the 60 kDa signal on
the silver stain was relatively low, this is representative of a final
protein concentration of 15 mg/ml and benefits from little to no
background signal arising from oligomeric forms as well as any
other additional protein contaminant.
Figure 3. Surface expression of hGLUT9b in X. laevis oocytes. (A) Expression level of hGLUT9b by Western blot analysis. (B) Surface expression
of hGLUT9b as determined by deglycosylation analysis using PNGase of fully denatured DDM based total lysate. (C) Surface biotinylation and pull-
down reveals a highly enriched hGLUT9b surface membrane fraction.
doi:10.1371/journal.pone.0108852.g003
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3D-Reconstruction of SLC2A9b Monomers
One of the main goals of this study was to determine if the
correlative model of the divergent hGLUT9 (Figure 2) was
accurate enough for further biochemical and predictive approach-
es. A single particle reconstruction (SPR) approach using the
monomeric state of purified hGLUT9 was used to compare our
initial predicted results with low-resolution images of isolation
protein of Fraction 35 from the SEC. By focusing on Fraction 35
protein negatively stained was enriched for monomeric represen-
tations of SLC2A9 (Figure S2).
The monomeric SLC2A9 3D-model was generated by single
particle reconstruction (SPR) utilizing EMAN2 suite. The aim of
‘‘single particle’’ image processing is to obtain a 3D-reconstruction
of a macromolecule from a large set of 1,439 particle images
obtained from TEM. The single particle reconstruction approach
is based on the assumption that the sample is homogeneous and
that particles are randomly oriented on EM grid, generating
different projections. Micrographs of a field of negatively stained
SLC2A9 monomers were used to generate particles for SPR
(Figure 6C). The quality of the micrograph is demonstrated by
the inset FFT. A particle set was isolated from the micrographs
with a total of 9 class averages (0–8), representing different
orientations (front, top and side) of the particles (Figure 6C).
From the class averages, an initial model was generated
(Figure 7A). The larger projections were approximately
85665 A˚ and maintained ovular shapes. The v-shaped projection
and more rectangular projection and were aligned to represent the
side views of hGLUT9, respectively (Figure 7A (i) and (ii)). The
smaller, circular projections represent the top and bottom view,
respectively (Figure 7A (iii) and (iv)). Presence of the particles
in different orientations, as represented by the Euler plot
(Figure 7B), indicated that there was even distribution of
hGLUT9b monomers on the support film with only minor
insufficiency between W906 and W180u due to the limitations
inherent with negative staining and the glow-discharge techniques.
After three iterative refinement process, a 3D-model at low-
resolution was generated to assess to the validity of our predictive
model. Based on the Fourier Shell Correlation, FSC = 0.5, we
tested the resolution of our models using the script e2resolution
within EMAN2 and obtained a 30 A˚ result for the initial model
and 23 A˚ resolution after further refinement (Figure 7B). An
overlay of the refined 3-D reconstruction model generated from
the TEM micrographs matches reasonably with the predicted
homology-based structure of hGLUT9 as shown in Figure 7C.
To aid in the interpretation of the model, we used the ‘‘Fit in
Map’’ function within Chimera to align the predicted structure
with the generated density map. Notably, two regions, (labeled
‘‘*’’) obtained after single particle reconstructions, were not fill by
the predictive structure. This is due to the rigid fitting method
employed in the predictive crystallographic structure not repre-
senting the potential dynamics of the protein structure that involve
movement of secondary domains.
Discussion
In the present study, we developed a model of the human uric
acid transporter GLUT9 and established protocols for the
expression, purification, and functional analysis of hGLUT9 using
the X. laevis oocyte expression system. The aim of this work was
two-fold. The first goal was to detail procedures for functional
expression of human GLUT9 protein to allow subsequent
biochemistry and structure-function analysis. This work is of
considerable interest as it is currently unknown why GLUT9 is
unique amongst GLUT family members in its ability to transport
uric acid. Physiologically, humans have one of the highest serum
uric acid levels among mammals, and a greater understanding of
the structure function of one of the main uric acid transporters
may lead to advancements in the treatment of gout as well as the
determining the role uric acid may play in neuro-protection and
oxidative stress. The second goal was to determine if GLUT9,
which shares the least homology with other members of the SLC2
family, could be sufficiently modelled from the recently published
bacterial homologue XylE. The modelling of hGLUT9 is a
prerequisite for the determination of a putative binding pocket for
uric acid, but due to a lack of sequence identity and the phylogenic
distance of hGLUT9, we developed a low-resolution single-
particle reconstruction of the human protein purified from X.
laevis oocytes in an environment that favours the native
Figure 4. Functional analysis of hGLUT9b in X. laevis oocytes.
(A) Water injected controls and hGLUT9b expressing oocytes were
clamped at 230 mV and exposed for 30 sec to 500 mM urate
containing OR2 medium. Current evoked by urate averaged 70+/2
10 nA (n.20). (B) Same experiment as outlined above, but with
application of the non-specific GLUT9 inhibitor, phloretin. Oocyte were
clamped at 230 mV and exposed for 15 sec to 500 mM urate followed
by 20 sec of 500 mM urate +25 mM Phloretin. Phloretin inhibited uric
acid current by 4564% (n = 3).
doi:10.1371/journal.pone.0108852.g004
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monomeric state. An alignment of the 23 A˚ representation
revealed significant overlap with the surface model generated
from the bacterial homologue, suggesting that the preliminary
model may be sufficient for determining putative binding sites.
Within the oocyte system, hGLUT9 had good expression with
sufficient protein yields to allow for gel filtration and isolation of
the monomeric state. In the past, we have found that the detergent
DDM was suitable for structural analysis of membrane proteins
isolated from oocytes and verified this process indeed worked well
for hGLUT9. Over expressed protein was observable in as little as
J of an oocyte and the subsequent isolated protein was detected
in Western blot and silver stain. Protein was further purified by
size-exclusion chromatography. Fraction 35 was chosen from this
gel filtration step as corresponding to the highest percentage of
monomeric hGLUT9 (Figure S2). Isolation of a single purified
oligomeric state improves subsequent single particle reconstruc-
tion, however we demonstrate that multiple states do exist. The
protein is likely represented in significant quantities as a dimeric or
tetrameric assembly and due to the DDM detergent and
purification steps, the monomeric form predominates. While
Fraction 35 of the SEC is monomerically enriched, Figure S2
demonstrates the presence of the multimeric form of hGLUT9.
Evidence for tetrameric assembly of other GLUT family members
has been demonstrated previously, but this is the first report of the
multimeric potential of human GLUT9 [21]. An interesting follow
up experiment would be to confirm the native oligomeric state
stabilized through cross-linking experiments which would be more
suitable for single particle reconstruction because of its size and
supramolecular organization.
The X. laevis oocyte expression system offers the ability to
simultaneously express human membrane protein and functionally
verify the expression through biochemical and electrophysiological
experimentation. With the use of the robotized HiClamp two-
electrode voltage clamp system, we were able to rapidly verify
functional expression of GLUT9. Oocytes expressing hGLUT9
demonstrate strong phloretin sensitive signals averaging 80 nA.
Phloretin, a non-specific inhibitor of hGLUT9, reduced the
current by nearly 50%, which is consistent with previous work [3].
The surface expression of hGLUT9 was verified by two
independent experiments. Like all members of the GLUT family,
hGLUT9 contains an extracellular glycosylation site. This post-
translational modification attaches a carbohydrate through an
enzymatic reaction within the ER subsequent to surface expression
of hGLUT9. Protein deglyocosylation via application of PNGase
revealed a significant shift in the mobility of hGLUT9 suggesting
that the majority of expressed protein was glycosylated. While
deglycosylation indicates the proper expression and folding of
hGLUT9, the potential remains that the glycosylated protein may
still not be expressed at the cell surface. To further indicate the
presence of hGLUT9 at the plasma membrane we performed
membrane biotinylation, in which surface labelled protein was
isolated for hGLUT9 expression indicating the majority of
expressed hGLUT9 was indeed present at the plasma membrane.
Through the combination of electrophysiology, enzymatic degly-
cosylation, and surface biotinylation, it was revealed that the
oocyte expression of hGLUT9 produced significant amounts of
properly folded, functional protein at the plasma membrane. For
future structure-function analysis, the oocyte system remains a
solid model for the functional expression and purification of
human hGLUT9 protein.
From 1500 injected oocytes, the amount of purified protein was
sufficient to establish gel filtration chromatography and isolate
different states of the protein. Monomeric form was separated
from aggregate in the objective to obtain pure and homogenous
sample for subsequent structural investigation by TEM in negative
staining. The quantity of protein isolated, approx. 15 mg/ml,
permitted single particle analysis and 3D reconstruction. The class
averages allowed for the generation of an initial 3D model with
sufficient similarity to our predictive crystal structure allowing for
additional refinement to reach a 23 A˚ resolution. The final density
map overlays well with the homology-based model but contains a
few regions that extend beyond the predicted model. The
differences arise from the origins of the XylE structure used to
determine our original model. When deriving a crystal structure,
Figure 5. SDS-PAGE, silver staining and Western blot analyses hGLUT9b purification after IMAC from X. laevis oocytes membrane
preparation. (A) Silver-stained and (B) Western blot SDS/polyacrylamide gels show that recombinant human GLUT9b runs at ,60 kDa,
corresponding to the expected molecular weight. Oligomers are observed at ,120 and 200 kDa. First line corresponds to the pellet fraction at
5,000 g after membrane solubilization (P5000) and the supernatant was loaded on the IMAC column (Input). The Western blot using anti-HA shows
that all hGLUT9b was extracted and solubilized from the membrane fraction. The three following lanes correspond to the unbound and washed
fractions and demonstrate that hGLUT9b binds to the column. The protein was eluted using HRV 3C protease at the PreScission site.
doi:10.1371/journal.pone.0108852.g005
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Figure 6. Isolation of hGLUT9b by size-exclusion chromatography with Western blot, silver stain, and single particle analysis. (A)
Superose 6 gel filtration chromatography shows two peaks. The first peak corresponds to the dead volume of the gel filtration where large molecular
weight proteins or aggregates do not interact with the beads and quickly pass through the column. The second peak corresponds principally to the
monomeric (sharp peak, right side) and oligomeric (shoulder, left side) states. Western blot representation of fractions 30 to 43 after gel filtration
showing clearly the separation of the second peak into hGLUT9b oligomers and monomer. (B) Silver-staining of hGLUT9b monomers obtained from
fraction 35. (C) Micrograph of hGLUT9 particles obtained from negatively-stained TEM. Scale bar is 50 nm. Gallery representation of the 9 class-
averages obtained from 1439 particles. Each representation is scaled to a 26 nm square.
doi:10.1371/journal.pone.0108852.g006
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the crystal lattice is constrained to one conformation whereas SPR
involves numerous conformations and diversity, especially among
regions which are dynamic and unstructured, as is likely the case
for the C-terminal domain and extracellular loop marked by an
asterisk (*) in Figure 7. The differences in our observations
obtained from SPR and homology-based modelling could reflect
the conditions used in our approach where the protein is
solubilized, physically absorbed to a grid, and finally stained.
Moreover, hGLUT9 is considered too small to expect fine details
in the structure due to the resolution restrictions when using
negative stain techniques. The contrast observed is due to the
staining, or protein ‘‘shadow’’, and not to the physical structure of
the protein, as would be the case in cryo-EM. Cryo-EM can be
significantly more sensitive with 3D reconstruction possible at
medium resolution [22]. However, the number of particles
required is exponentially higher due to the lower levels of contrast
and decreased signal to noise ratios observed in cryo-EM.
Moreover, for all TEM methods, detergents surround the
solubilized membrane protein. These detergents become part of
the overall particle and could contribute to the conformation of
the protein or permit the interpretation of a false extension or form
within the structure. This is made more evident using negative
staining, as detergents appear on the micrograph as high-contrast
signals similar to protein. Nevertheless, our result indicate our
predictive model is defined well within the density map and serves
to provide initial evidence towards our goal to determine if the
predicted model is suitable for docking approaches that will help to
identify the amino acids involved in the binding and transport of
urate.
As an exercise to determine the potential benefits of the
homology based hGLUT9 structure, we created a surface model
using PyMOL v0.99. Here we discovered an interior cavity
aligned to the binding pocket for D-xylose co-crystallized with the
bacterial homologue XylE. While subsequent work will need to
validate our hyopthesis, it could be extrapolated that this is the
binding pocket for urate in hGLUT9. Figure 8 describes this
cavity in which we extrapolated from the surface model the amino
acids potentially involved in the binding of the urate: H23, R31,
Figure 7. Single particle reconstruction of purified hGLUT9b monomers. (A) Different views of the initial 3D-reconstruction (gray surface)
which accommodate the predicted homology-based model (gold). Scale bar is 26 A˚. (B) Plot of the Euler angle distribution showing that the particles
adsorb to the carbon film in random and uniformly distributed orientations. The initial model was determined to have a resolution of 30 A˚ as
estimated using a Fourier Shell Correlation curve. The refined model improved the resolution to a final 23 A˚ (C). The final refined model showing the
original homology based-structure within the density map of the observed hGLUT9 particles. Alignment showed significant overlap with two areas
noted by an asterisk corresponding to unstructured domains.
doi:10.1371/journal.pone.0108852.g007
Structural Insights for the hGLUT9
PLOS ONE | www.plosone.org 11 October 2014 | Volume 9 | Issue 10 | e108852
Figure 8. Hypothetical Substrate Binding Pocket in hGLUT9 model. (A) The surface modeling of hGLTU9, as described in Figure 2, was used
to determine a 3 A˚- pocket that could serve as a hypothetical substrate-binding site. (B) The putative binding site found is formed by amino acids:
H23, R31, L182, Q203, A206, Q328, L332, N333, F426, W459 and N462.
doi:10.1371/journal.pone.0108852.g008
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L182, Q203, A206, Q328, L332, N333, F426, W459 and N462.
The putative urate binding site domain is constrained within trans-
membrane region 1 (TM1-orange), TM4 (yellow), TM5 (purple),
TM7 (cyan), TM10 green, and TM11 (blue). These results
generate a restricted list of potential sites for subsequent
mutagenesis. The next step will utilize the predictive structure of
hGLUT9 to define docking simulations with urate and verify the
precise amino acids interacting with the substrate. Structure
function relationship will be planed with single or combined
mutagenesis and the function will be accessed by previously
defined electrophysiology combined with radiolabelled C14 urate
uptake assays. The identification of the urate binding site will be
compared to the glucose-binding site of hGLUT1–4 in order to
reveal the mystery of substrate specificity in hGLUT9 and
potentially lead to novel pre-clinical modulators for this physio-
logically relevant transporter.
In general, our results satisfied our goals to express and purify
functional human GLUT9 in the Xenopus laevis model system.
We went an additional step towards subsequent structure-function
studies by creating a homology-based structure of hGLUT9. We
verified the overall strategy by aligning our model within a 23 A˚
single particle reconstruction of the purified human protein. A
putative binding pocket for the substrate urate was determined
based off of the homology model, leaving the door open for site-
directed mutagenesis and a greater understanding of the
biophysical properties of one of the most distinct and physiological
significant members of the SLC2 family members.
Supporting Information
Figure S1 Sequence Alignment for XylE and SLC2A
human family homologues. Similar color code for amino
acids was chosen as Figure 1. Alignment was performed using
SeaViewer 4 NCBI Blast sequences.
(TIFF)
Figure S2 Single particle analysis of Fraction 35 reveals
potential multimeric forms of hGLUT9. (A) Representative
electron micrograph of negative stained monomeric and dimeric
hGLUT9 particles resulting from fraction 35 of the size exclusion
chromatography (SEC). Black rings represent the dominant
monomeric form, while white rings indicate possible dimeric
particles as demonstrated by the SEC analysis below. Scale bar is
75 nm. (B) Individual images representing monomeric and
dimeric particles isolated from the micrograph. Scale bar is 13 nm.
(TIFF)
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